Researchers examined a random sample of health insurance claim records of 16 million patients in the United States between 2006 and 2020 for use of semaglutide drugs.
A new report from ISMP Canada shares what doctors, pharmacists, anaesthesiologists and others should do about the increased risk of aspiration after anesthesia for people taking GLP-1 receptor agonists like semaglutide.
B.C. study finds no benefit in reducing death or COVID-related hospitalization in lower-risk individuals, including those 70 years or older who were not moderately or severely immunocompromised.
Public formularies are starting to cover biosimilar insulins instead of their reference biologic drugs and it is predicted that this will save millions of dollars annually.